This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- beta-Sitosterol
- DrugBank Accession Number
- DB14038
- Background
Active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for beta-Sitosterol (DB14038)
- Weight
- Average: 414.718
Monoisotopic: 414.38616623 - Chemical Formula
- C29H50O
- Synonyms
- (-)-β-Sitosterol
- (24R)-Ethylcholest-5-en-3beta-ol
- (24R)-ethylcholest-5-en-3β-ol
- (24R)-Stigmast-5-en-3beta-ol
- (3β)-Stigmast-5-en-3-ol
- 22,23-Dihydrostigmasterol
- 24α-Ethylcholesterol
- Azuprostat
- Cupreol
- Nimbosterol
- Sitosterol
- Triastonal
- α-Dihydrofucosterol
- β-Sitosterin
- External IDs
- SKF 14463
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Burned ••• ••• •••••••• Treatment of Periodontal diseases ••• ••• ••••• •••••• Treatment of Wounds ••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Harzol
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Insadol Tablet 35 mg/1 Oral OASIS TRADING 2018-11-20 Not applicable US 
Insadol Tablet 35 mg/1 Oral I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US Insadol Tablet 35 mg/1 Oral Lydia Co., Ltd. 2019-10-08 Not applicable US มีโบ Ointment 0.25 %w/w Topical บริษัท มีโบ จำกัด 1999-04-08 Not applicable Thailand 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BP Vit 3 beta-Sitosterol (200 mg/1) + Cyanocobalamin (500 ug/1) + Doconexent (350 mg/1) + Folic acid (1 mg/1) + Icosapent (35 mg/1) + Omega-3 fatty acids (500 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) Capsule, coated Oral Acella Pharmaceuticals, LLC 2009-04-17 Not applicable US Insadol beta-Sitosterol (35 mg/1) Tablet Oral Lydia Co., Ltd. 2019-10-08 Not applicable US Insadol beta-Sitosterol (35 mg/1) Tablet Oral I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US Insadol beta-Sitosterol (35 mg/1) Tablet Oral OASIS TRADING 2018-11-20 Not applicable US Mi-Omega NF beta-Sitosterol (200 mg/1) + Cyanocobalamin (500 ug/1) + Folic acid (1 mg/1) + Omega-3-acid ethyl esters (500 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) Capsule Oral Mayne Pharma Inc. 2009-01-01 2016-05-31 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as stigmastanes and derivatives. These are sterol lipids with a structure based on the stigmastane skeleton, which consists of a cholestane moiety bearing an ethyl group at the carbon atom C24.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Stigmastanes and derivatives
- Direct Parent
- Stigmastanes and derivatives
- Alternative Parents
- Triterpenoids / C24-propyl sterols and derivatives / 3-beta-hydroxysteroids / 3-beta-hydroxy delta-5-steroids / Delta-5-steroids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
- Substituents
- 3-beta-hydroxy-delta-5-steroid / 3-beta-hydroxysteroid / 3-hydroxy-delta-5-steroid / 3-hydroxysteroid / Alcohol / Aliphatic homopolycyclic compound / C24-propyl-sterol-skeleton / Cyclic alcohol / Delta-5-steroid / Hydrocarbon derivative
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3beta-sterol, phytosterols (CHEBI:27693) / stigmastane, Stigmasterols and C24-ethyl derivatives (C01753) / Stigmasterols and C24-ethyl derivatives (LMST01040129)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S347WMO6M4
- CAS number
- 83-46-5
- InChI Key
- KZJWDPNRJALLNS-VJSFXXLFSA-N
- InChI
- InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1
- IUPAC Name
- (1R,3aS,3bS,7S,9aR,9bS,11aR)-1-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol
- SMILES
- [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000852
- KEGG Drug
- D08518
- KEGG Compound
- C01753
- ChemSpider
- 192962
- BindingDB
- 50218197
- 47070
- ChEBI
- 27693
- ChEMBL
- CHEMBL221542
- ZINC
- ZINC000004095717
- Wikipedia
- Beta-Sitosterol
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Basic Science High Cholesterol / Indication for Carotid Endarterectomy / Symptomatic Carotid Stenosis 1 somestatus stop reason just information to hide 2 Completed Treatment Chronic Periodontitis (Disorder) 1 somestatus stop reason just information to hide 1, 2 Unknown Status Treatment Graft Pain / Recession, Gingival 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 35 mg/1 Capsule Oral Capsule, coated Oral Capsule, gelatin coated Oral Ointment Topical 0.25 %w/w - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.84e-05 mg/mL ALOGPS logP 7.27 ALOGPS logP 7.84 Chemaxon logS -7.4 ALOGPS pKa (Strongest Acidic) 18.2 Chemaxon pKa (Strongest Basic) -1.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 20.23 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 129.77 m3·mol-1 Chemaxon Polarizability 54.21 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 219.1820579 predictedDarkChem Lite v0.1.0 [M-H]- 224.8486579 predictedDarkChem Lite v0.1.0 [M-H]- 213.2335579 predictedDarkChem Lite v0.1.0 [M-H]- 222.7302579 predictedDarkChem Lite v0.1.0 [M-H]- 194.16098 predictedDeepCCS 1.0 (2019) [M+H]+ 219.9549579 predictedDarkChem Lite v0.1.0 [M+H]+ 225.2509579 predictedDarkChem Lite v0.1.0 [M+H]+ 213.5245579 predictedDarkChem Lite v0.1.0 [M+H]+ 224.3025579 predictedDarkChem Lite v0.1.0 [M+H]+ 196.33229 predictedDeepCCS 1.0 (2019) [M+Na]+ 218.9363579 predictedDarkChem Lite v0.1.0 [M+Na]+ 224.6677579 predictedDarkChem Lite v0.1.0 [M+Na]+ 213.3205579 predictedDarkChem Lite v0.1.0 [M+Na]+ 222.7031579 predictedDarkChem Lite v0.1.0 [M+Na]+ 202.60577 predictedDeepCCS 1.0 (2019)
Drug created at May 17, 2018 20:50 / Updated at June 12, 2020 16:53